Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2019 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab

KENSINGTON, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain,...
October 21, 2019 09:45 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit

KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
October 21, 2019 08:30 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman

KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
October 08, 2019 09:35 ET | Source: Galimedix

Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting

KENSINGTON, Md. and SHORASHIM, Israel , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., which is developing new solutions for neurodegenerative diseases of the retina and the brain,...
May 08, 2019 08:00 ET | Source: Galimedix

Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models

KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data...
May 06, 2019 07:00 ET | Source: Galimedix

Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors

KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the...
February 11, 2019 08:30 ET | Source: Galimedix

Galimedix Therapeutics to Present at the BIO CEO & Investor Conference

KENSINGTON, Md. and SHORASHIM, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced...
February 06, 2019 09:35 ET | Source: Galimedix

Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference

KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an...
January 29, 2019 08:30 ET | Source: Galimedix

Galimedix Therapeutics to Participate in the 8th Annual Glaucoma 360 Conference

KENSINGTON, Md. and SHORASHIM, Israel, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced its...
December 11, 2018 08:30 ET | Source: Galimedix

Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer

KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the...